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Abstract: This study shows that prostaglandins in human FM55
melanoma cells and epidermal melanocytes are produced by
COX-1. Prostaglandin production in FM55 melanoma cells was
unrelated to that of melanin suggesting that the two processes can
occur independently. a-Melanocyte-stimulating hormone, which
had no effect on melanin production in FM55 cells, stimulated
PGD2 production in these cells without affecting PGE2. While
cAMP pathways may be involved in regulating PGD2 production,
our results suggest that a-MSH acts independently of cAMP,
possibly by regulating the activity of lipocalin-type PGD synthase.
This a-MSH-mediated effect may be associated with its role as an
immune modulator.
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Background
Melanocytes produce melanin and have a role in skin pig-
mentation (1,2). Cutaneous prostaglandins, such as PGE2
and PGF2a, may act as mediators in this process because
they increase melanocyte dendricity and melanogenesis
(3,4). It has been suggested that these prostaglandins arise
from keratinocytes (4) but it is possible that they are also
produced by melanocytes acting as autocrine factors in the
pigmentary response.
However, prostaglandins have a wide range of biological
activities, and while some such as PGE2 act as pro-inﬂam-
matory mediators (5), others such as PGD2 down-regulate
immune responses (6). PGD2 is formed by prostaglandin D
synthase (EC 5.3.99.2) (PGDS), an isoform of which, lipoc-
alin-PGDS (L-PGDS), is expressed in pigment cells (7).
Expression of L-PGDS is dependent upon microphthalmia-
associated transcription factor (MITF) (7) which is acti-
vated via cAMP and is involved in regulating melanogene-
sis (1,8,9). Thus, it is possible that PGD2 production is
associated with melanogenesis, and the two processes have
a common regulatory pathway.
a-Melanocyte-stimulating hormone (a-MSH) regulates
melanogenesis via the cAMP-coupled melanocortin 1
receptor (MC1R) expressed on melanocytes (10–12). This
peptide is also a potent immunomodulator through its
effects on MC1R expressing immune cells such as mono-
cytes and macrophages (13). Because melanocytes are
immunocompetent (14–16), they might also mediate
immunomodulatory actions of a-MSH. Their production
of prostaglandins and, speciﬁcally, PGD2 could therefore be
associated with this function.
Questions addressed
Is the production of prostaglandins related to that of mela-
nin in pigment-producing cells, and is it regulated by
a-MSH?
Experimental design
Prostaglandins were measured in melanin-producing FM55
human melanoma cells (17) and in human epidermal
melanocytes. FM55 cells were used as a model system to
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nin production and the effect of a-MSH. Because their
MC1R does not couple to cAMP FM55 cells do not
produce melanin in response to a-MSH (18). Their use
therefore allowed the possibility of dissociating prostaglan-
din production from that of melanin.
The lightly pigmented FM55 cells were established from
metastatic melanoma nodules (Dr AF Kirkin, Danish Can-
cer Society, Copenhagen, Denmark). Human epidermal
melanocytes were isolated from skin samples obtained with
local ethics committee approval and informed consent
from donors undergoing elective plastic surgery. Cell cul-
ture (19,20), eicosanoid analysis (21), stimulation and mea-
surement of melanin (20,22) and COX-1⁄-2 protein
expression (5) were performed as published; L-PGDS was
measured using an immunometric kit (Appendix S1).
Results
PGD2 and PGE2 were the major prostaglandins identiﬁed
in human epidermal melanocytes and FM55 melanoma
cells (Fig. 1a, b). Lipidomic analysis did not conﬁrm pro-
duction of PGF2a by FM55, as previously reported using a
less speciﬁc radiometric approach (17). Western blotting
analysis revealed that FM55 cells and melanocytes expressed
the constitutive isoform of cyclooxygenase (COX-1) but
not the inducible isoform COX-2 (Fig. 1c, d).
Increasing melanin production in FM55 had no effect on
prostaglandin production (Fig. 2a, b); when prostaglandins
were stimulated with arachidonic acid, melanin production
was not affected (23 ± 6 and 24 ± 4 lg melanin⁄mg cell
protein, before and after treatment, respectively).
a-MSH had no effect on PGE2 production in FM55 cells
but increased PGD2 and PGD1 with no effect on melanin
(Fig. 2c). 3-Isobutyl-1-methylxanthine (IBMX), which raises
cAMP levels by inhibiting phosphodiesterase, increased the
production of PGD2 and, in contrast to a-MSH, increased
melanin production (Fig. 2c). As shown in Fig. 2d, the
effect of a-MSH on PGD2 production was dose-related, the
maximal increase occurring in response to 10
)8m a-MSH, a
dose within the physiological range of concentrations of
*
**
0
500
1000
1500
2000
2500
p
g
 
P
G
/
m
g
 
p
r
o
t
e
i
n Control
AA (10 µM)
**
**
0
1500
3000
4500
6000
7500
9000
PGD2 PGE2 PGJ2 PGD2 PGE2 PGJ2
p
g
 
P
G
/
m
g
 
p
r
o
t
e
i
n
Control
AA (10 µM)
F39 (a)
(c)
COX-2
(73 kDa)
Actin
(43 kDa)
MW
(kDa)
100
80
60
40
2
(b)
(d)
1 2 MW
100
80
60
40
(kDa)
F55
34
 COX-1 
(72 kDa)
 Actin 
(43 kDa)
 COX-1 
(72 kDa)
 Actin 
(43 kDa)
COX-2
(73 kDa)
Actin
(43 kDa)
34
Figure 1. Sample proﬁle of prostaglandins (PG) produced by human
epidermal melanocytes F39 (a) and human melanoma FM55 (b) under
resting conditions (Control) and following treatment with arachidonic
acid (AA) (10 lM for 24 h). Expression of COX-1 and COX-2 proteins in
human epidermal melanocytes F39 (c) and human melanoma FM55
cells (d) assessed by Western blotting analysis. MW: molecular weight
markers; Lane 1: COX-1; Lane 2: COX-1+ COX-1 blocking peptide;
Lane 3: COX-2; Lane 4: COX-2-positive control using FM3 hamster
melanoma cells. Note: each antibody (i.e. COX-1 and COX-2) was
independently carried on its own lane of the same gel. Data shown as
mean ± SEM of n = 3 independent experiments. *P < 0.05 and
**P < 0.005, comparing data to control.
Melanin PGD1 PGD2 PGE2
(µg/mg protein) (pg/mg protein) (pg/mg protein) (pg/mg protein)
Control 13.7 ± 1.3 27 ± 5 16 ± 11
α-MSH (10–8 M) 9.7 ± 0.6 22 ± 6 51 ± 16 *
IBMX (10–4 M) 9.5 ± 2.2 * 99 ± 41 *** 30 ±  3
110 ± 26 61 ± 29
357 ± 94 ** 89 ± 25
299 ± 53 * 135 ± 75
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Figure 2. Prostaglandin (PG) and melanin production in FM55 human
melanoma cells. The effect of NH4Cl (10 mM) and L-tyrosine (400 lM)
on (a) melanogenesis and (b) prostaglandin production. (c) The effect of
a-Melanocyte-stimulating hormone (a-MSH) (10
)8
M) and IBMX (10
)4
M)
on cell number, levels of melanin, PGD1, PGD2 and PGE2, following 48-
h treatment. Dose-dependent effect of a-MSH (10
)10–10
)7
M) on (d)
PGD1 and PGD2 production and (e) lipocalin-prostaglandin D synthase
expression. Data expressed as mean ± SEM of n = 3 independent
experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 comparing data
to control (CTR). (f) Schematic outline of the major signalling pathways
involved in melanin and PGD2 production. In FM55 cells, the MC1R
does not couple to cAMP as indicated by the cross. As a consequence,
a-MSH fails to stimulate melanin production, and the regulation of
PGD2 production may be via a cAMP independent pathway as indicated
by the dotted line. AA, arachidonic acid; PGH2, prostaglandin H2;
MC1R, melanocortin 1 receptor; MITF, microphthalmia-associated
transcription factor.
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)7m, a-MSH reduced
PGD2 to control levels. Similar changes were seen with
PGD1. L-PGDS was present in FM55 melanoma cells, but
protein levels were unaffected by a-MSH (Fig. 2e).
Conclusion
It has been suggested that prostaglandins have a role in the
pigmentary response (3,4). However, we found no such
association between prostaglandin and melanin production
in FM55 melanoma cells. This dissociation was further
demonstrated in experiments with a-MSH. Although this
peptide is melanogenic in human melanocytes via the
MC1R (10,11), it fails to have this effect in FM55 cells
(18), as conﬁrmed here, yet it increased prostaglandin pro-
duction. Thus, it would seem that in FM55 cells prosta-
glandins are produced as part of some non-pigmentary
function.
PGD2 is a major prostaglandin in both epidermal mela-
nocytes and FM55 cells. a-MSH modulated the production
of PGD2 in a concentration-dependent manner in FM55,
producing a bell-shaped dose response curve similar to that
observed for melanin (10) and NO (15). As with many of
its actions, it seems that a-MSH is a modulator rather than
an outright stimulator.
a-MSH may act speciﬁcally to regulate PGD2 synthesis at
the level of L-PGDS (Fig. 2f). This is supported by the con-
comitant stimulation on PGD1 but lack of effect on PGE2,
indicating that a-MSH is not acting at the level of COX.
Our ﬁndings indicate that a-MSH may affect the activity,
but not expression of L-PGDS. Expression of L-PGDS is
upregulated by MITF (7), which is under the control of the
cAMP signalling pathway (23). This would explain the
increase in PGD2 production observed in response to
IBMX-dependent increased cAMP. It is unlikely that a-
MSH acts in this way because the MC1R on FM55 cells
does not couple to cAMP (18). We therefore propose that
a-MSH acts independently of cAMP and activates L-PGDS
rather than inducing its expression. Further studies using
human epidermal melanocytes and melanoma cells with
different degrees of pigmentation are needed to elucidate
this effect of a-MSH and determine whether it is a com-
mon property of pigment-producing cells.
PGD2 can inhibit growth of human melanoma cells (24)
and loss of L-PGDS expression may be important in allow-
ing the tumor to avoid immune surveillance (25). The fact
that PGD2 is a product of immune cells, such as Langer-
hans cells, mast cells and macrophages (26) emphasizes its
importance as an immunomodulator. Melanocytes are
another potential source of cutaneous PGD2; this together
with the regulation of PGD2 production by a-MSH under-
lines their importance as mediators of immune responses
in the skin.
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